Results 91 to 100 of about 25,289 (245)

Comparative Effects of Angiotensin Receptor Blockers on Blood Pressure and Serum Urate in Patients With Hypertension and Hyperuricaemia: A Systematic Review and Network Meta‐Analysis

Medicine Bulletin, EarlyView.
Allisartan ranked best for serum urate reduction and showed favourable blood pressure control, whereas losartan also performed well overall. These rankings may inform ARB selection but should be interpreted cautiously because of inconsistency, heterogeneity and sparse direct evidence.
Xuanyao Li, Xinyi Wang, Xiaolei Ren, Yalin Wang, Hua Shao, Xueli Zhang   +5 more
wiley   +1 more source

Amlodipine and valsartan as components of a rational and effective fixed-dose combination

, 2009
Bernard Waeber1, Luis M Ruilope21Division of Clinical Pathophysiology, University Hospital, Faculty of Biology and Medicine, University of Lausanne, Switzerland; 2Hypertension Unit, Hospital 12 de Octubre, Madrid, SpainAbstract: Pharmacological treatment
Luis M Ruilope, Bernard Waeber
core  

Exanthematous drug eruption due to valsartan

, 2012
Objective: Valsartan is an angiotensin II receptor blocker (ARB) used for treatment of hypertension. The well-known adverse effects of valsartan are dizziness, headache and cough.
Turkmen, Meltem, Senturk, Bircan, Ozturk, Gunseli, Kandiloglu, Gulsen, Turk, Bengu Gerceker   +4 more
core   +1 more source

AI‐Enabled Cardiac Rehabilitation for Patients With Heart Failure After Myocardial Infarction: Current Status and Future Prospects

Medicine Advances, EarlyView.
This article illustrates the current dilemmas of myocardial infarction patients after traditional cardiac rehabilitation, as well as the feasibility of using artificial intelligence to optimize and assist with rehabilitation programs such as by integrating mobile apps, wearables, ECGs, medication, vital signs, and assessment data; finally, the AI ...
Xinyuan Huang, Di Chen, Yumin Cai, Zihan Chen, Dongmei Xie, Chaoquan Peng, Yuanlong Li   +6 more
wiley   +1 more source

Add-On Aliskiren Elicits Stronger Renoprotection Than High-Dose Valsartan in Type 2 Diabetic KKAy Mice That Do Not Respond to Low-Dose Valsartan

Journal of Pharmacological Sciences, 2012
We hypothesized that aliskiren provides renoprotection in diabetic animals that did not receive sufficient renoprotection by AT1-receptor antagonist treatment.
Bai Lei, Daisuke Nakano, Yu-Yan Fan, Kento Kitada, Hirofumi Hitomi, Hiroyuki Kobori, Hirohito Mori, Tsutomu Masaki, Akira Nishiyama   +8 more
doaj   +1 more source

Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program

, 2011
Ivo Abraham1,2, Karen MacDonald2, Christine Hermans3, Ann Aerts3, Christopher Lee2,4, Heidi Brié3, Stefaan Vancayzeele31Center for Health Outcomes and Pharmacoeconomic Research, and Department of Pharmacy Practice and Science, College of Pharmacy,
Abraham I
core  

The evaluation of valsartan biopharmaceutics properties.

, 2020
Background: Solubility, intestinal permeability and dissolution are the main factors that govern the rate and extent of drugs absorption and are directly related to bioavailability.
Souza, Jacqueline de, Caldeira, Tamires Guedes, Barcellos, Neila Marcia Silva, Mapa, Bruna de Carvalho, Gomes, Bruna Pegorelli, Croce, Carolina Carvalho Della, Castro, Lara Maria Lopes de, Soares, Anna Flávia Matos   +7 more
core   +1 more source

Integrative Approaches in Cardiovascular Disease: The Role of Nutraceuticals in Heart Failure, Atrial Fibrillation, and Related Conditions

Phytotherapy Research, EarlyView.
Schematic representation of the shared pathophysiological mechanisms underlying heart failure (HF) and atrial fibrillation (AF), including inflammation, oxidative stress, endothelial dysfunction, and fibrosis. The figure highlights the clinical and mechanistic convergence of conventional pharmacological therapies and selected nutraceuticals in ...
Laura Beatrice Mattioli, Ivan Corazza, Roberta Budriesi, Luca Camarda, Maria Carelli, Alberto Spadotto, Igor Diemberger   +6 more
wiley   +1 more source

THE COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF GENERIC AND ORIGINAL VALSARTAN AS A MONOTHERAPY OR IN COMBINATION WITH HYDROCHLOROTHIAZIDE AND BISOPROLOL IN PATIENTS WITH ARTERIAL HYPERTENSION OF 1-2 DEGREE AND METABOLIC SYNDROME

Рациональная фармакотерапия в кардиологии, 2015
Aim. To study the efficacy and safety of generic valsartan Valz (Actavis Group, Iceland) in comparison with the original valsartan Diovan® (Novartis, Switzerland) in patients with arterial hypertension (HT) of 1-2 degrees and metabolic syndrome. Material
S. Yu. Martsevich, Yu. V. Lukina, N. A. Dmitrieva, O. V. Lerman, S. N. Tolpygina, V. P. Voronina, L. Yu. Drozdova   +6 more
doaj   +1 more source

Randomized study to compare valsartan ± HCTZ versus amlodipine ± HCTZ strategies to maximize blood pressure control

, 2009
Dion Zappe1, Cheraz Cherif Papst2, Philippe Ferber3, On behalf of the PROMPT investigators1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 2Novartis Pharma Ag, Basel, Switzerland; 3Roche Pharmaceuticals, Basel, SwitzerlandObjective: Delays ...
Dion Zappe, Cheraz Cherif Papst, Philippe Ferber, et al.   +3 more
core